PepGen

Treating neuromuscular diseases requires precision delivery across some of the body’s toughest biological barriers.

PepGen is developing next-generation therapies with enhanced tissue penetration. Its platform targets the root causes of diseases such as myotonic dystrophy type 1 – offering new hope for patients with few treatment options. The company was listed on US NASDAQ in 2022.